No CrossRef data available.
Article contents
Decisions about treatment with targeted therapies in a palliative care unit: A case series
Published online by Cambridge University Press: 22 August 2022
Abstract
Background
Early palliative care integration into the oncologic treatment pattern is recognized and strongly recommended to anticipate end-of-life issues and avoid disproportionate care. Targeted therapies (TTs), with their very rapid onset of action and relatively good tolerance, may have an effect on cancer-related symptoms, which could be beneficial in the context of palliative care.
Methods
Data were extracted from a cohort of all patients hospitalized in an acute palliative care unit between 03.04.2019 and 07.04.2020. Data for all consecutive patients for which a decision on a TT was made during hospitalization were retrospectively analyzed.
Results
Forty-two patients were identified. Thirty-one patients were currently receiving TT on admission. For 19/31 (61.3%) patients, the treatment was discontinued. The remaining 12 patients had TT after discharge from the palliative care unit (continuation of the same TT or modification of the TT during the stay), with an average duration of 208 days and an average of 46 days between the last TT and death. TT was introduced or reintroduced in 7 patients of the 11 patients hospitalized without treatment at admission. In this group, the average duration of treatment was 28 days, with an average of 28 days between the last TT and death. Five of the patients who received re-challenged TT experienced a subjective improvement of their symptom.
Significance of results
TT was discontinued in the majority of our patients. However, in some cases, the treatment was maintained because it was effective on cancer-related symptoms even at the end of life. However, this should not overshadow the palliative process. The continuation or introduction of a specific oncological treatment requires close cooperation between oncologists and palliative care physicians and an honest and clear explanation to patients and their families.
- Type
- Original Article
- Information
- Copyright
- Copyright © The Author(s), 2022. Published by Cambridge University Press
References
REFERENCES
Colombet, I, Bouleuc, C, Piolot, A, et al. (2019) Multicentre analysis of intensity of care at the end-of-life in patients with advanced cancer, combining health administrative data with hospital records: Variations in practice call for routine quality evaluation. BMC Palliative Care 18.CrossRefGoogle ScholarPubMed
Delaye, M, Scotte, F, Voisin-Saltiel, S, et al. (2020) Using targeted therapies at the end of life. BMJ Support Palliative Care. doi:10.1136/bmjspcare-2020-002529.Google ScholarPubMed
Fang, P, Jagsi, R, He, W, et al. (2019) Rising and falling trends in the use of chemotherapy and targeted therapy near the end of life in older patients with cancer. Journal of Clinical Oncology 37(20), 1721–1731.CrossRefGoogle ScholarPubMed
Gogas, HJ, Flaherty, KT, Dummer, R, et al. (2019) Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: Incidence, course and management. European Journal of Cancer 119, 97–106.10.1016/j.ejca.2019.07.016CrossRefGoogle ScholarPubMed
Goldwasser, F, Nisenbaum, N, Vinant, P, et al. (2018) [Multidisciplinary oncopalliative meeting: Aims and pratical recommendations]. Bulletin du Cancer 105, 458–464.CrossRefGoogle ScholarPubMed
Jang, T-K, Kim, D-Y, Lee, S-W, et al. (2018) Trends in treatment during the last stages of life in end-stage gynecologic cancer patients who received active palliative chemotherapy: A comparative analysis of 10-year data in a single institution. BMC Palliative Care 17(1), 99.CrossRefGoogle ScholarPubMed
Mathew, A, Achkar, T, Abberbock, S, et al. (2017) Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer. Breast Journal 23(6), 718–722.CrossRefGoogle ScholarPubMed
Pacetti, P, Paganini, G, Orlandi, M, et al. (2015) Chemotherapy in the last 30 days of life of advanced cancer patients. Support Care Cancer 23(11), 3277–3280.CrossRefGoogle ScholarPubMed
Prigerson, HG, Bao, Y, Shah, MA, et al. (2015) Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncology 1(6), 778–784.CrossRefGoogle ScholarPubMed
Schreuer, M, Jansen, Y, Planken, S, et al. (2017) Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: An open-label, single arm, dual-centre, phase 2 clinical trial. The Lancet. Oncology 18(4), 464–472.CrossRefGoogle Scholar
Soh, TIP, Yuen, Y-C, Teo, C, et al. (2012) Targeted therapy at the end of life in advanced cancer patients. Joural of Palliative and Medicine 15(9), 991–997.CrossRefGoogle ScholarPubMed
Wright, AA, Zhang, B, Keating, NL, et al. (2014) Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: Prospective cohort study. BMJ 348, g1219.CrossRefGoogle ScholarPubMed